Seiko Solutions Corporation (President and CEO: Jun Sekine, Headquarters: Chiba City, Chiba Prefecture, hereinafter Seiko Solutions) announced that its AI knowledge platform "Seiko Futureworks" has been adopted for the proofreading of pharmaceutical information materials by Pharma International Inc. (President and CEO: Masaki Yamagata, Headquarters: Chuo-ku, Tokyo, hereinafter Pharma International). Both companies jointly conducted a trial for approximately three months from December 2025, verifying the effectiveness of AI proofreading on a total of 8 materials, including patient booklets, interview records, pamphlets, and academic conference records, from multiple perspectives such as initial reading, manuscript collation, material consistency, and specialized terminology. After two tuning sessions, the system achieved improved detection accuracy and reduced false positives, and full-scale operations began in April 2026. For this adoption, Pharma International was responsible for providing on-site knowledge of proofreading operations and evaluation, while Seiko Solutions provided the Seiko Futureworks platform, implementation support, tuning, and operational support. [Background] Pharmaceutical information materials play a crucial role in conveying accurate information about the efficacy and safety of drugs to healthcare professionals and patients. Proofreading requires confirmation from a wide range of perspectives, including typographical errors, inconsistencies in notation, uniformity of terminology, consistency, collation with manuscripts and original texts, and compliance with creation guidelines. Pharma International, which has over 50 pharmaceutical companies as clients and plans and produces more than 4,000 pharmaceutical information materials annually, has continuously promoted initiatives to ensure quality, such as establishing an internal education system for thorough regulatory compliance. However, to achieve further quality improvement and operational